与APRIL、BAFF和CD40L融合的三聚体HIV-1 gp140对小鼠黏膜gp140特异性抗体应答的影响
研究将APRIL、BAFF和CD40L分别与HIV-1 gp140三聚体融合,采用DNA初免-蛋白加强方案免疫小鼠。结果显示gp140-APRIL和gp140-BAFF融合蛋白分别轻度促进阴道灌洗液或粪粒中gp140结合IgG应答并降低血清IgA,而gp140-CD40L抑制黏膜和全身抗体应答。作者认为APRIL和BAFF值得进一步探索作为HIV-1疫苗分子佐剂。
要点
- gp140-APRIL和gp140-BAFF轻度促进小鼠阴道灌洗液或粪粒中gp140结合IgG。
- gp140-APRIL还增强血清中gp140结合IgG。
- gp140-CD40L抑制黏膜和全身gp140结合IgG或IgA。
核心结论
- APRIL和BAFF值得进一步探索作为HIV-1疫苗分子佐剂以增强黏膜抗体应答,但TNFSF与gp140共价融合可能因空间相互作用而妨碍其佐剂作用。
研究设计与样本
- 研究构建了TNFSF分子APRIL、BAFF和CD40L分别与HIV-1 gp140三聚体的融合 construct,并在小鼠中采用DNA初免-蛋白加强免疫方案测试融合 construct 诱导的黏膜gp140特异性抗体。
主要发现
- 融合 construct 可形成三聚体并展示广谱中和抗体表位和非广谱中和抗体表位。
- 与对照 construct 三聚体gp140相比,gp140-APRIL和gp140-BAFF融合蛋白体外轻度促进B细胞增殖,分别增强阴道灌洗液或粪粒中HIV-1 gp140结合IgG应答,并降低血清中HIV-1 gp140结合IgA。
- gp140-APRIL还增强血清中HIV-1 gp140结合IgG。
- gp140-CD40L体外不促进B细胞增殖,并抑制黏膜和全身HIV-1 gp140结合IgG或IgA。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HIV-1 envelope (Env)-specific antibody present at mucosal surfaces can block entry of HIV-1 into these portals and thus should be elicited by an HIV-1 preventive vaccine. Since three molecules of tumor necrosis factor superfamily (TNFSF), APRIL, BAFF, and CD40L, could promote mucosal antibody responses, we made fusion constructs of them with an HIV-1 gp140 trimer and tested the mucosal gp140-specific antibody elicited by the fusion constructs in mice using a DNA prime-protein boost vaccination regimen. The fusion constructs formed trimers and displayed both broadly neutralizing antibody epitopes and non-broadly neutralizing antibody epitopes. Compared with the control construct, trimeric gp140, trimeric gp140-APRIL and gp140-BAFF fusion proteins mildly promoted B cell proliferation in vitro, enhanced HIV-1 gp140-binding IgG responses in vaginal lavage or fecal pellets, respectively, and decreased HIV-1 gp140-binding IgA in sera. Gp140-APRIL also augmented HIV-1 gp140-binding IgG in sera. Surprisingly, gp140-CD40L did not promote B cell proliferation in vitro and inhibited mucosal and systemic HIV-1 gp140-binding IgG or IgA. These results suggest that APRIL and BAFF should be further explored as molecular adjuvants for HIV-1 vaccines to enhance mucosal antibody responses, but covalent fusion of TNFSFs to gp140 may hinder their adjuvancy due to steric interactions.
引用
- Liu J, Clayton K, Gao W, et al. Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice. Vaccine. 2020. PMID: 32014267. doi:10.1016/j.vaccine.2020.01.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。